Switch theme
Sign up to access all valuation multiples
SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.
n/a
LTM Revenue $297M
LTM EBITDA -$37.0M
$2.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SK Bioscience has a last 12-month revenue (LTM) of $297M and a last 12-month EBITDA of -$37.0M.
In the most recent fiscal year, SK Bioscience achieved revenue of $194M and an EBITDA of -$26.3M.
SK Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SK Bioscience valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $297M | XXX | $194M | XXX | XXX | XXX |
| Gross Profit | $69.5M | XXX | $22.5M | XXX | XXX | XXX |
| Gross Margin | 23% | XXX | 12% | XXX | XXX | XXX |
| EBITDA | -$37.0M | XXX | -$26.3M | XXX | XXX | XXX |
| EBITDA Margin | -12% | XXX | -14% | XXX | XXX | XXX |
| EBIT | -$83.0M | XXX | -$101M | XXX | XXX | XXX |
| EBIT Margin | -28% | XXX | -52% | XXX | XXX | XXX |
| Net Profit | -$41.9M | XXX | -$39.2M | XXX | XXX | XXX |
| Net Margin | -14% | XXX | -20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $51.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, SK Bioscience's stock price is KRW 45100 (or $33).
SK Bioscience has current market cap of KRW 3.46T (or $2.5B), and EV of KRW 2.68T (or $2.0B).
See SK Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.0B | $2.5B | XXX | XXX | XXX | XXX | $-0.53 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, SK Bioscience has market cap of $2.5B and EV of $2.0B.
SK Bioscience's trades at 10.0x EV/Revenue multiple, and -74.2x EV/EBITDA.
Equity research analysts estimate SK Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SK Bioscience has a P/E ratio of -60.1x.
See valuation multiples for SK Bioscience and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV (current) | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EV/Revenue | 6.6x | XXX | 10.0x | XXX | XXX | XXX |
| EV/EBITDA | -52.7x | XXX | -74.2x | XXX | XXX | XXX |
| EV/EBIT | -23.5x | XXX | -19.4x | XXX | XXX | XXX |
| EV/Gross Profit | 28.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -60.1x | XXX | -64.3x | XXX | XXX | XXX |
| EV/FCF | -10.4x | XXX | -8.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSK Bioscience's last 12 month revenue growth is 56%
SK Bioscience's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
SK Bioscience's rule of 40 is 68% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SK Bioscience's rule of X is 128% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for SK Bioscience and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 56% | XXX | 59% | XXX | XXX | XXX |
| EBITDA Margin | -12% | XXX | -14% | XXX | XXX | XXX |
| EBITDA Growth | -157% | XXX | -40% | XXX | XXX | XXX |
| Rule of 40 | 68% | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 128% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 63% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SK Bioscience acquired XXX companies to date.
Last acquisition by SK Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . SK Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is SK Bioscience headquartered? | SK Bioscience is headquartered in South Korea. |
| Is SK Bioscience publicy listed? | Yes, SK Bioscience is a public company listed on KRX. |
| What is the stock symbol of SK Bioscience? | SK Bioscience trades under 302440 ticker. |
| When did SK Bioscience go public? | SK Bioscience went public in 2021. |
| Who are competitors of SK Bioscience? | Similar companies to SK Bioscience include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of SK Bioscience? | SK Bioscience's current market cap is $2.5B |
| What is the current revenue of SK Bioscience? | SK Bioscience's last 12 months revenue is $297M. |
| What is the current revenue growth of SK Bioscience? | SK Bioscience revenue growth (NTM/LTM) is 56%. |
| What is the current EV/Revenue multiple of SK Bioscience? | Current revenue multiple of SK Bioscience is 6.6x. |
| Is SK Bioscience profitable? | Yes, SK Bioscience is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of SK Bioscience? | SK Bioscience's last 12 months EBITDA is -$37.0M. |
| What is SK Bioscience's EBITDA margin? | SK Bioscience's last 12 months EBITDA margin is -12%. |
| What is the current EV/EBITDA multiple of SK Bioscience? | Current EBITDA multiple of SK Bioscience is -52.7x. |
| What is the current FCF of SK Bioscience? | SK Bioscience's last 12 months FCF is -$187M. |
| What is SK Bioscience's FCF margin? | SK Bioscience's last 12 months FCF margin is -63%. |
| What is the current EV/FCF multiple of SK Bioscience? | Current FCF multiple of SK Bioscience is -10.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
